A Phase Ib/II Multicenter Open-label Modular Dose-Finding and Dose Expansion Study to Explore the Safety Tolerability and Anti-tumor Activity of Trastuzumab Deruxtecan (DS-8201a T-DXd) in Combination with other Anti-cancer Agents in Patients with Metastatic HER2-positive Breast Cancer (DESTINY-Breast07)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Her2-positive Metastatic Breast Cancer
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Have been diagnosed with advanced/metastatic HER2-postiive breast cancer. 2) Have received at least 1 prior treatment line in metastatic setting. A treatment line may consist of endocrine therapy, chemotherapy and/or anti-HER2 therapy, or a combination of any of these.
You may not be eligible for this study if the following are true:
-
1) Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements. 2) Has untreated central nervous system metastases identified either on the baseline brain imaging obtained during the screening period or identified.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
